Sanofi Q3 2024 Adj. EPS $1.57 Up From $1.39 YoY, Sales $14.796B Beat $13.970B Estimate
Portfolio Pulse from Benzinga Newsdesk
Sanofi reported a strong Q3 2024 with adjusted EPS of $1.57, a 12.95% increase from last year, and sales of $14.796 billion, beating estimates by 5.91%.
October 25, 2024 | 5:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's Q3 2024 earnings report shows a significant increase in both EPS and sales, surpassing analyst expectations.
Sanofi's Q3 2024 earnings per share increased by 12.95% compared to the previous year, and sales exceeded analyst estimates by 5.91%. This strong performance is likely to positively impact the stock price in the short term as it indicates robust financial health and growth.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100